![Chemical constituents of Litsea elliptica and their alpha-glucosidase inhibition with molecular docking Phoopha S, Wattanapiromsakul C, Pitakbut T, Dej-adisai S - Phcog Mag Chemical constituents of Litsea elliptica and their alpha-glucosidase inhibition with molecular docking Phoopha S, Wattanapiromsakul C, Pitakbut T, Dej-adisai S - Phcog Mag](https://www.phcog.com/articles/2020/16/70/images/PhcogMag_2020_16_70_327_293765_t7.jpg)
Chemical constituents of Litsea elliptica and their alpha-glucosidase inhibition with molecular docking Phoopha S, Wattanapiromsakul C, Pitakbut T, Dej-adisai S - Phcog Mag
![Great Expectations: A Critical Review of and Suggestions for the Study of Reward Processing as a Cause and Predictor of Depression - ScienceDirect Great Expectations: A Critical Review of and Suggestions for the Study of Reward Processing as a Cause and Predictor of Depression - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006322320317005-gr2.jpg)
Great Expectations: A Critical Review of and Suggestions for the Study of Reward Processing as a Cause and Predictor of Depression - ScienceDirect
![2009R0043 — SK — 01.01.2010 — 005.002 Tento dokument slúži čisto na potrebu dokumentácie a inštitúcie nenesú nijakú zodpovednosť za jeho obsah B NARIADENIE RADY (ES) č. 43/2009, z 16. januára 2009 ktorým sa na rok 2009 stanovujú rybolovné ... 2009R0043 — SK — 01.01.2010 — 005.002 Tento dokument slúži čisto na potrebu dokumentácie a inštitúcie nenesú nijakú zodpovednosť za jeho obsah B NARIADENIE RADY (ES) č. 43/2009, z 16. januára 2009 ktorým sa na rok 2009 stanovujú rybolovné ...](https://eur-lex.europa.eu/resource.html?uri=celex:02009R0043-20100101.SLK.xhtml.L_2009022SK.01017501.tif.jpg)
2009R0043 — SK — 01.01.2010 — 005.002 Tento dokument slúži čisto na potrebu dokumentácie a inštitúcie nenesú nijakú zodpovednosť za jeho obsah B NARIADENIE RADY (ES) č. 43/2009, z 16. januára 2009 ktorým sa na rok 2009 stanovujú rybolovné ...
![Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-020-00357-4/MediaObjects/41408_2020_357_Fig1_HTML.png)